Lv28
150 积分 2025-11-16 加入
Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial
13天前
已完结
First-In-Human Phase 1/2a Study of the First-In-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
13天前
已完结
Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions
13天前
已完结
Disparities in stage at diagnosis for five common cancers in China: a multicentre, hospital-based, observational study
2个月前
已完结
Toxicity profiles of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors: safety analysis from clinical trials and the FDA Adverse Event Reporting System (FAERS)
4个月前
已完结
皖公网安备34019202002308
